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Background: The study aimed at examining hypoxia-inducible factor (HIF)1α expression in adenocarcinomas and
adenomas in bitches in regard to tumour malignancy grade, proliferation, apoptosis and vascularisation. Therefore,
paraffin sections of 15 adenomas and 64 adenocarcinomas sampled from 79 dogs aged 6 to 16 years were analysed.
Results: A significantly higher HIF-1α expression was noted in adenocarcinomas in comparison to adenomas
(P < 0.0004). Moreover, HIF-1α expression in adenocarcinomas correlated positively with tumour malignancy grade
(r = 0.59, P < 0.05), Ki-67 antigen expression (r = 0.43; P< 0.0005), TUNEL-positive cells (r = 0.62, P< 0001) and tumour
vascularity measured by quantification of vessels characterized by the expression of von Willebrand Factor (r = 0.57, P< 0.05).
Conclusion: Results of this study indicate a similar biological role of HIF-1α in dogs and in humans, which may confirm
suitability of the animal model in investigations on progression of tumours in humans.
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Neoplastic cells and cells of malignant tumours at their
preliminary stage of development are supplied, in particu-
lar, with oxygen and metabolic products via diffusion. This
secures conditions for their growth and attainment of a
tumour diameter not around 2 mm. Subsequent growth of
the tumour exceeding this size requires additional supply
provided by blood vessels. Therefore, hypoxia develops
within neoplastic tissue and tumour cells begin to manifest
an increased demand for glucose and an accelerated gly-
colysis, in such conditions securing the principal source of
ATP [1]. Glycolysis was shown to progress very efficiently
in tumours growing in hypoxic conditions since they ex-
press hypoxia-inducible factor (HIF-1). This factor is re-
sponsible for an increased expression of several proteins,
including glycolytic enzymes such as hexokinase-1 and −3,
phosphofructokinase L, aldolase A and C, phosphoglycer-
ate kinase-1, enolase-1, lactate dehydrogenase and the so
called glucose transporters GLUT-1 and GLUT-3 [1]. In-
tensity of glucose uptake by tumour cells was found to* Correspondence: marcin.nowak@up.wroc.pl
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reproduction in any medium, provided the ormanifest positive correlation with their aggressiveness [1].
Moreover, HIF-1 stimulates tumour growth by activation of
the VEGF gene transcription, which codes for vascular
endothelial growth factor, the principal inducer of angio-
genesis. In the absence of neovascularization tumour
growth would be inhibited or even the tumour would show
regression. Anti-neoplastic therapy takes advantage of this
phenomenon by inhibiting angiogenesis in a tumour e.g.
using monoclonal VEGF-specific antibodies [1,2]. It should
be added that HIF-1 stimulates also transcription of IGF2
gene, coding for insulin-like growth factor 2 (IGF2), which
facilitates survival of tumour cells also in an environment
with an diminished oxygen content [1,3].
HIF-1 is a heterodimer, consisting of HIF-1α and HIF-
1β subunits. The HIF-1β subunit undergoes a constitutive
expression while the expression of HIF-1α is low in most
cells in normoxia conditions. Inhibition of HIF-1α expres-
sion results from activity of oxygen-dependent hydroxy-
lases which enzymatically modify HIF-1α chain enabling
its binding with von Hippel-Lindau tumour suppressor
protein (VHL) [4]. In turn, VHL acts as a recognition fac-
tor for ubiquitin-protein ligase E3, which directs HIF-1α
to degradation in proteasomes [5,6]. In normoxia condi-
tions, half-life of HIF-1α protein is very short but ittd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of HIF-1α synthesis utilizes the signalling pathway leading
to a tyrosine kinase receptor, such as HER2 (Human
Epidermal Growth Factor Receptor 2), with mediation
of phosphatidylinositol-3-kinase (PI3K), serine/threonine
kinases (AKT) and mammalian target for rapamycin
(mTOR) [8]. The signalling pathway is inhibited by PTEN
protein (phosphatase and tensin homologue deleted on
chromosome ten), which dephosphorylates the product of
PI3K reaction [1]. Therefore, HIF-1 may be regarded as a
factor, which allows the cells to adapt to low tissue levels
of oxygen.
Our study aimed at demonstration of HIF-1α protein
expression and determination of its intensity in the most
frequently manifested malignant and benign mammary
tumours of epithelial origin (adenocarcinomas and aden-
omas) in bitches. Moreover, an attempt was made to
correlate the obtained results with expression levels of
the Ki-67 proliferation antigen and with blood vessel
density of the tumours.
Methods
The research we performed was approved and financed
by the National Science Center of Poland. As this
research was performed on archival material routinely
collected during surgical-treatment procedures and no
additional harm was done to the animals due to the
experiments, we did not require an additional ethics
approval for our research. All the experiments were
performed on disposable material which were not uti-
lized for future scientific experiments. Only paraffin-
embedded tissues were used for the study.
Tissue material and immunohistochemistry (IHC)
Material for the study was sampled during surgery in 79
female dogs of various breeds, aged 6 to 16 years. The tu-
mours were verified by histopathological examination of
the HE sections and represented adenomas (15 cases) and
adenocarcinomas (64 cases).
Formalin-fixed, paraffin-embedded tissue was freshly
cut (4 μm). The sections were mounted on Superfrost
Plus slides (Menzel Gläser, Braunschweig Germany) and
subsequently deparaffinised by boiling in Antigen Re-
trieval Solution (High pH = 9 for HIF-1α, Low pH = 6
for Ki-67; DakoCytomation, Glostrup, Denmark) using
PT Link Rinse Station (DakoCytomation). Then, the sec-
tions were incubated (20 min; room temperature, RT)
in Link48 automated staining platform (DakoCyto-
mation) utilizing murine primary monoclonal antibodies
diluted in the Background Reducing Antibody Diluent
(DakoCytomation) and directed against HIF-1α (1:600;
Novus Biologicals, Littleton, USA), von Willbrand Fac-
tor (vWF; 1:800; DakoCytomation) or Ki-67 (ready-
to-use, DakoCytomation). The visualization of the studiedantigens was performed using EnVision FLEX (Dako-
Cytomation), according to the manufacturer’s instruc-
tions. All the sections were counterstained with Meyer’s
hematoxylin. In all the cases, controls were included, in
which specific antibody was substituted by the Primary
Negative Control (DakoCytomation).
Apoptosis detection was performed utilizing the
ApopTag® Peroxidase In Situ Apoptosis Detection Kit
(Millipore, Billerica, USA). Paraffin sections were dewaxed
in xylene, rehydrated in alcohol and rinsed in distilled
water and 1xPBS, pH 7.4. Then, the sections were incu-
bated in Proteinase K (DakoCytomation) for 5 min in RT
and rinsed in 1xPBS. Endogenous peroxidase was blocked
by 5 min incubation in 3% H2O2/1xPBS. Subsequently,
the sections were incubated with Equilibration Buffer for
10 min in RT, with subsequent incubation with TdT En-
zyme and Reaction Buffer at 37°C for 1 h. The reaction
was stopped after 10 min incubation in the Stop Buffer
and rinsed in 1xPBS. Then, anti-dioxygenin peroxidase-
conjugated antibodies were applied for 30 min at RT. Fol-
lowing that, the sections were incubated for 10 min with
diaminobenzidine (DAB; DakoCytomation) to visualize
the TUNEL-positive cell nuclei. Finally, the sections were
counterstained with Mayer’s hematoxylin and, after de-
hydration in alcohols, mounted in SUB-X Mounting
Medium (both DakoCytomation).
Quantification of IHC reactions
Microphotographs of all the studied tumours were sub-
jected to computer-assisted image analysis via a com-
puter coupled to an Olympus BX53 optical microscope
(Olympus, Japan). The set had the potential to record
images and to perform their digital analysis. The mea-
surements took advantage of CellA software (Olympus
Soft Imaging Solution GmbH, Germany).
Microscope examination allowed determination of the
malignancy grade of the adenocarcinomas. The grade was
established using the scale of Bloom-Richardson in modi-
fication of Elston and Ellis [9]. The evaluation method of
the malignancy grade included three parameters scored in
the scale from 0 to 3 points: formation of tubules (evident,
moderate, slight), polymorphism of cell nuclei (slight,
moderate, marked), number of mitotic figures per 10
microscope fields at the magnification of × 400 (0–7, 8–
16, ≥ 17). The sum of the points provided potential to dis-
tinguish three malignancy grades (G) among the tumours:
0–5 pts. – G1, 6–7 pts. – G2, 8–9 pts. – G3.
Expression of HIF-1α was appraised using the modified
semi-quantitative immunoreactive score (IRS) scale ac-
cording to Remmele (Table 1) [10]. The method takes into
account both proportion of positively stained cells and in-
tensity of the colour reaction, while the final score is the
product of the parameters, with values ranging from 0 to
12 points (no reaction = 0 points (−); weak reaction = 1–2
Table 1 Semi-quantitative immunoreactive score (IRS)
taking into account both the percentage of stained cells
(A) and the intensity of reaction product (B) in which the





0 No cells with positive reaction No colour reaction
1 ≤ 10% Cells with positive reaction Low intensity of colour reaction
2 11-50% Cells with positive reaction Average intensity of colour reaction
3 51-80% Cells with positive reaction Intense colour reaction
4 > 80% Cells with positive reaction
Figure 1 Immunohistochemical expression of HIF-1α in adenoma (A)
(C) and TUNEL in cancer cells (D). Von Willbrand Factor (vWF) expression in
Magnification × 200 (A-D); ×40 (E-F).
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reaction = 6–12 points (+++)).
Microvessel density (MVD) of vWF-positive vessels was
quantified under × 200 magnification in five intratumoural
areas of the lesion and the final score was determined as a
mean of the five quantified areas.
The Ki-67 antigen expression and TUNEL stained sec-
tions were scored under × 400 magnification in five areas,
in which number of positive cells presenting brown reac-
tion colour were counted. The final score represented the
percentage of positive tumour cells to all tumour cells in
the examined sections.
Statistical analysis
The results were subjected to statistical analysis using
Prism 5.0 (GraphPad, La Jolla, USA) software, employing
Mann–Whitney test and Spearman’s correlation analysis.and adenocarcinoma (B). High expression intensity of Ki-67 antigen
endothelial cells noted in adenoma (E) and adenocarcinoma (F).
Figure 2 Hypoxia-inducible factor-1α (HIF-1α) expression in
adenomas and adenocarcinomas (A) and in relation to the
grade of malignancy of the studied adenocarcinomas (B).
***P < 0.001; ****P < 0.0001, Mann–Whitney test.
Figure 3 Correlations between expressions of HIF-1α, Ki-67 antigen
(A), TUNEL (B) and vWF MVD (C) in the analyzed adenocarcinomas.
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Results
Expression of HIF-1α protein was demonstrated both in
mammary adenomas and adenocarcinomas in bitches
(Figures 1A, 1B). In all the cases with positive reaction
(90% adenocarcinomas and in 86% adenomas) a nuclear-
cytoplasmic HIF-1α expression was noted. Moreover, in
the two groups of tumours evident differences were seen
in intensity of the protein expression. In adenocarcin-
omas, over 39% tumours manifested HIF-1α expression
evaluated at +, over 26% expression evaluated at ++ and
25% at +++. In adenomas, 86% of the examined tumours
manifested expression of the protein which, however, did
not exceed the +intensity. It should be noted that over
9% of adenocarcinomas and over 13% of adenomas
manifested no HIF-1α expression. Statistical analysis using
Mann-Whitney test demonstrated a significantly higher
HIF-1α expression in adenocarcinomas than in adenomas
(P = 0.0004) (Figure 2A).
The relationship between distribution of HIF-1α expres-
sion intensity and malignancy grade was also of interest. InG1 adenocarcinomas almost 28% of the tumours ma-
nifested no HIF-1α expression, 61% of them manifested
the expression at + level and 11% at ++ level. In cases
of G2 adenocarcinomas, 3% of the tumours manifested no
HIF-1α expression, over 37% showed + expression, over
37% of them demonstrated ++ expression and almost
22% +++ expression. G3 adenocarcinomas exhibited HIF-
1α expression at + level in over 14% of cases, at ++ level in
over 28% of cases and at +++ level in over 57% of cases.
It should be added that only in the group of G3
Figure 4 Von Willbrand Factor mean vascular density (vWF
MVD) in adenomas and adenocarcinomas (A) and in relation to
the grade of malignancy of the studied adenocarcinomas (B).
***P < 0.001, Mann–Whitney test.
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high expression of the protein (+++) while no such strong
HIF-1α expression could be noted in G1 or G2 tumours.
Spearman’s correlation test demonstrated a pronounced
positive correlation between HIF-1α expression and tu-
mour malignancy grade (r = 0.59; P < 0.05). Mann–Whitney
test revealed significant differences in HIF-1α expres-
sion between particular malignancy grades of adenocar-
cinomas (G1 vs. G2 - P < 0.0001; G1 vs. G3 - P < 0.0001;
G2 vs. G3 – P = 0.02) (Figure 2B).
Tumour cell proliferation was determined by assessing
the expression of the Ki-67 antigen (Figure 1C). Similarly,
positive correlations were disclosed between tumour’s ma-
lignancy grade and expression of Ki-67 proliferation anti-
gen (r = 0.61; P < 0.0001), and between expressions of
HIF-1α and Ki-67 (r = 0.43; P < 0.0005; Figure 3A).
Studies on intensity of apoptosis using the TUNEL ap-
proach (Figure 1D) demonstrated that level of apoptosis
in canine mammary adenocarcinomas manifested posi-
tive correlation with expression of HIF-1α protein and
the correlation demonstrated a high level (r = 0.62; P <
0.0001; Figure 3B).An extremely important and interesting aspect of the
study was the examination of a correlation between HIF-
1α protein expression and vWF MVD (Figures 1E, 1F).
Both in adenomas and in adenocarcinomas the corre-
lation proved to be pronounced and positive. Its level was
slightly higher in malignant tumours (adenocarcinomas:
r = 0.57; P < 0.05; Figure 3C) than in benign tumours (ad-
enomas r = 0.52; P < 0.05). Mann–Whitney test demon-
strated significant differences in vWF MVD between
individual malignancy grades (G1 vs. G2 – P = 0.251; G1
vs. G3 – P = 0.098; G2 vs. G3 – P = 0.586) – Figure 4.
Discussion
Immunohistochemical studies on human tumours dem-
onstrated pronounced expression of HIF-1α in many
common tumours, which probably represents a conse-
quence of both hypoxia within the tumour and various
genetic disturbances in neoplastic cells [11]. Moreover,
HIF-1α expression was shown to manifest positive corre-
lation with expression of VEGF and with density of
microvessels in most of tumours of central nervous sys-
tem [12], ovarian cancer [13], ductal mammary carcinoma
[14], colon adenocarcinoma [15], endometrial adenocar-
cinoma [16], ductal pancreatic adenocarcinoma [17],
small-cell pulmonary carcinoma [18]. The relationship
seems to be of significance since not only elevated HIF-1α
expression is linked to increased VEGF levels, but absence
of HIF-1α expression in several cases results in a de-
creased VEGF level and, thus, an inhibited process of
neoangiogenesis. The latter observation has been corrobo-
rated in studies on embryonal stem cells of mice devoid
of HIF-1α expression, in which VEGF mRNA level was
markedly decreased and could not be induced by hypoxia.
Similarly in our study we have demonstrated a pro-
nounced positive correlation between expression of HIF-
1α and density of microvessels both in a malignant
(adenocarcinoma) and benign (adenoma) tumours, even if
in the latter case the correlation has shown a slightly
lower level. However, it should be added that some re-
ports documented absence of a significant correlation be-
tween expressions of mRNA for HIF-1α and VEGF in
hypophyseal adenomas [19]. Their authors suggested that
in such tumours VEGF expression may exhibit no pro-
nounced dependence on expression of HIF-1α.
A very important element of HIF-1α biological activity is
the induction of protein synthesis involved, i.a., in develop-
ment of metastases, including vimentin, fibronectin, meta-
lloproteinase 2, cathepsin D, urokinase-type plasminogen
activator receptor (uPAR). Moreover, HIF-1α protein can
induce a decrease in E-cadherin expression, the protein im-
portant for cell adhesion [20]. In studies on in vitro inva-
siveness of human pulmonary adenocarcinoma cells, Shyu
et al. [21] demonstrated that in conditions of normoxia,
HIF-1α manifested expression in cells presenting high
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noted in cells of a low invasiveness (CL1). In parallel, the
authors found that an increased HIF-1α expression in cells
of human pulmonary carcinoma was linked to their in-
creased invasiveness, probably due to an increased expres-
sion of uPAR receptor and metalloproteinase 1 and 2
(MMP1 and MMP2). In our study we have analogously
found that HIF-1α expression has manifested positive cor-
relation with certain prognostically unfavourable traits of
the tumours, i.e., with malignancy grade and proliferative
potential, reflected in expression of the Ki-67 antigen.
Shin et al. [18] found that levels of HIF-1α and VEGF
mRNA expression were higher in tissues of an early or ad-
vanced colon carcinoma than in colon adenoma. They
suggested that MMP-2, HIF-1α and VEGF might repre-
sent useful parameters for detection of early carcinogen-
esis and progression of colon carcinoma. In turn, Osada
et al. [13] showed that HIF-1α expression in cell nucleus
and HIF-2α in cytoplasm of neoplastic cells was linked to
an unfavourable prognosis in women with ovarian carcin-
oma. The authors found also that HIF-1α expression in
cell nucleus represented an independent prognostic factor
in women with such a cancer. Similar results were
obtained by Daponte et al. [22], who noted that survival
of females with serous ovarian carcinoma, the cells of
which demonstrated strong HIF-1α expression, was sig-
nificantly abbreviated as compared to patients in whom
neoplastic cells showed low or no HIF-1α expression. A
pronounced expression of HIF-1α is linked to an in-
creased risk of death at early stages of various types of
malignant tumours, including carcinomas of uterine cer-
vix, esophageal, mammary carcinoma and cerebral oligo-
dendroglioma [12,23-25]. Moreover, reports are available
which show that, augmented expression of HIF-1α corre-
lated with a increased apoptosis of neoplastic cells [25,26].
Similarly, in our investigations on canine mammary
adenocarcinomas we have found that an increased HIF-1α
expression was paralleled by higher levels of apoptosis
among neoplastic cells. This may indicate that certain
tumour cell subpopulations are more sensitive to an in-
creasingly intense hypoxia. Moreover, it has been demon-
strated that experimentally induced overexpression of
HIF-1α in cells of non-small-cell pulmonary carcinoma
(line A549) inhibits tumour development, i.a., through a
more pronounced apoptosis [3].
Conclusions
High expression of HIF-1α in neoplastic cells, expressing
their adjustment to hypoxia conditions in the tumour, in
the course of why some tumours may provide a useful
marker of canine tumour aggressiveness based on ob-
served positive correlations with the tumour malignancy
grade and the Ki-67 antigen expression. The HIF-1α ex-
pression in mammary adenomas and adenocarcinomasof bitches may indicate that the biological role of the
protein is similar in tumours of canines and humans.
This may confirm suitability of using the animal model
in studies on progression of tumours in the man.
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